Increased levels of plasma IL-1b and BDNF can predict resistant depression patients

Author(s)

Uint, Luciana ^[1] ; Bastos, Gisele Medeiros ^[1] ; Thurow, Helena Strelow ^[2] ; Borges, Jessica Bassani ^{[2, 1]} ; Crespo Hirata, Thiago Dominguez ^[2] ; Dias Franca, Joao Itolo ^[1] ; Hirata, Mario Hiroyuki ^{[2, 1]} ; de Moraes Rego Sousa, Mamanda Guerra ^[1]

Affiliation

^[1] Dante Pazzanese Inst Cardiol, Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Sch Pharmaceut Sci, Sao Paulo, SP - Brazil

• Document type: Journal article
• Source: Revista da Associação Médica Brasileira; v. 65, n. 3, p. 361-369, MAR 2019.
• Web of Science Citations: 0

Abstract

SUMMARY BACKGROUND: There is no strong evidence on the link between inflammatory profile and pattern of drug treatment response in depressive patients that could result in Coronary Artery Disease occurrence. OBJECTIVE: This study aimed to compare the subclinical atherosclerosis markers, inflammatory profile, and BDNF production in Resistant Depression (RD) or Bipolar Affective Disorder (BAD) patients under conventional treatment. METHODS: The population evaluated was comprised of 34 RD, 43 BAD, and 41 controls. Subclinical atherosclerosis markers were evaluated using ultrasonography, tomography, and exercise stress test. Plasma concentrations of TNFα, IL-1β, IL-6, and BDNF were measured using Luminex100™. The usCRP concentration was measured using turbidimetric immunoassay. IL1B, IL6, and TNFA expression were determined using TaqMan®. For the statistical analysis, the significance level was established at p<0.05. RESULTS: Concerning subclinical atherosclerosis markers, only O2 consumption was reduced in the BAD group (p = 0.001). Although no differences were found in gene expression, BDNF and IL-1β plasma concentration was increased in the RD group (p = 0.002 and p = 0.005, respectively) even with an antidepressant treatment, which suggests that these drugs have no effect in IL-1β secretion and that the inflammasome may play a role in therapy response. CONCLUSION: Taken together, both BDNF and IL-1β plasma concentrations could be used to the early identification of RD patients. (AU)

• FAPESP's process: 11/22000-7 - Evaluation of plasma levels of C-reactive protein, interleukins and markers of subclinical atherosclerosis in patients with refractory unipolar depression or bipolar affective disorder
• Grantee: Amanda Guerra de Moraes Rego Souza
• Support Opportunities: Regular Research Grants